The Fifth Annual Kidney Health Initiative (KHI) Stakeholders Meeting and the Eighth Project Submission Cycle

By Katherine R. Tuttle, MD, FASN

The Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology (ASN) and the U.S. Food and Drug Administration (FDA), continues to advance its mission of facilitating innovation and patient safety in kidney disease through its collaborative partnership with the kidney community.

KHI is holding its Fifth Annual Stakeholders Meeting on May 24-25, 2017 in Silver Spring, MD. KHI appreciates the support of its growing membership - nearly 80 companies and organizations. The annual meeting will bring together members across different fields allowing them to share ideas, discuss ongoing projects, collect feedback, and collaborate on new projects. Of the more than 125 U.S. and international attendees, nearly a third represent FDA and government agencies, a third are affiliated with industry, and a third represent patients and health-care professionals.

The Fifth Annual KHI Stakeholders’ Meeting has been developed around the theme of precision medicine and its application to kidney diseases. A superb line-up of keynote addresses will be given by leading experts from diverse backgrounds. First, Eric Dishman, Director of the NIH’s All of Us Research Program, will give the opening address followed by Robert Star, MD, of the NIDDK and Katherine Donigan, PhD, of the FDA on Wednesday, May 24. Thomas Brown, MD, MBA, of the Swedish Cancer Institute and the Providence Precision Medicine Platform, along with Laura-Mae Baldwin, MD, MPH, of the Institute of Translational Health Sciences and University of Washington will address the KHI Stakeholders on Thursday, May 25. The meeting will also include breakout sessions to discuss current and future KHI activities that support the initiative’s Mission, including five project proposals.

KHI executes its mission-driven objectives through support of projects proposed by members across all areas of the kidney community. KHI’s eighth project proposal submission cycle is now open and accepting project proposals that align with strategic priorities: 

•    Advancement of Patient and Family Partnership and Funding of Kidney Diseases 
•    Biomarker and Pathogenesis Understanding 
•    Clinical Trial Endpoints and Design
•    Clinical Trial Infrastructure and Developing the Evidence Base 
•    Closer Collaboration with the FDA and Other Government Agencies 

During the current eighth project submission cycle, KHI has received the following five project proposals seeking endorsement from the KHI Board of Directors. These proposals reflect the rich diversity of KHI’s membership and interests as well as enormous prospects to positively impact prevention, diagnosis, treatment, and living with kidney diseases.

•    Empowering Patients to Choose Kidney Healthy Foods
•    Fostering Innovation in Fluid Management 
•    Identification of Appropriate Endpoints for Clinical Trials in Hyperoxaluria 
•    Surrogate Endpoints in Focal Segmental Glomerulosclerosis (FSGS)
•    Towards Minimizing Glucocorticoid Use in ANCA Vasculitis and Lupus Nephritis: Can Systematic Assessment of Glucocorticoid Induced Damage Pave the Way? 

Once the portal closes, the KHI Board of Directors will review the proposals, score them based on their feasibility, impact, and likelihood to meet the KHI Mission. Meritorious proposals will be officially endorsed this summer. Once endorsed by the Board, interested individuals can apply to serve on KHI project workgroups this fall. 

In its fifth year, KHI will continue to achieve growth and interaction among its diverse membership in order to facilitate development, dissemination, and implementation of drugs, devices, and biologics that improve kidney health. If interested in receiving more information about KHI or enrolling as a member, please contact the KHI staff at KHI@asn-online.org.

 

KHI would like to acknowledge and thank all of the members of the 2017 KHI Program Planning Committee for their efforts in planning and organizing the Fifth Annual KHI Stakeholders Meeting.

Matthew Breyer, MD, FASN
Michael Flessner, MD, PhD
Victor Gura, MD, FASN
Carolyn Y. Neuland, PhD
Uptal Patel, MD
Alan Perlman, MD
Katherine Tuttle, MD, Chair
Prabir Roy-Chaudhury, MD, PhD, KHI Co-Chair
David M. White, KHI PFPC Liaison

Category:
Author:
Katherine R. Tuttle, MD, FASN
Article Image:
Body:

The Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology (ASN) and the U.S. Food and Drug Administration (FDA), continues to advance its mission of facilitating innovation and patient safety in kidney disease through its collaborative partnership with the kidney community.

KHI is holding its Fifth Annual Stakeholders Meeting on May 24-25, 2017 in Silver Spring, MD. KHI appreciates the support of its growing membership - nearly 80 companies and organizations. The annual meeting will bring together members across different fields allowing them to share ideas, discuss ongoing projects, collect feedback, and collaborate on new projects. Of the more than 125 U.S. and international attendees, nearly a third represent FDA and government agencies, a third are affiliated with industry, and a third represent patients and health-care professionals.

The Fifth Annual KHI Stakeholders’ Meeting has been developed around the theme of precision medicine and its application to kidney diseases. A superb line-up of keynote addresses will be given by leading experts from diverse backgrounds. First, Eric Dishman, Director of the NIH’s All of Us Research Program, will give the opening address followed by Robert Star, MD, of the NIDDK and Katherine Donigan, PhD, of the FDA on Wednesday, May 24. Thomas Brown, MD, MBA, of the Swedish Cancer Institute and the Providence Precision Medicine Platform, along with Laura-Mae Baldwin, MD, MPH, of the Institute of Translational Health Sciences and University of Washington will address the KHI Stakeholders on Thursday, May 25. The meeting will also include breakout sessions to discuss current and future KHI activities that support the initiative’s Mission, including five project proposals.

KHI executes its mission-driven objectives through support of projects proposed by members across all areas of the kidney community. KHI’s eighth project proposal submission cycle is now open and accepting project proposals that align with strategic priorities: 

•    Advancement of Patient and Family Partnership and Funding of Kidney Diseases 
•    Biomarker and Pathogenesis Understanding 
•    Clinical Trial Endpoints and Design
•    Clinical Trial Infrastructure and Developing the Evidence Base 
•    Closer Collaboration with the FDA and Other Government Agencies 

During the current eighth project submission cycle, KHI has received the following five project proposals seeking endorsement from the KHI Board of Directors. These proposals reflect the rich diversity of KHI’s membership and interests as well as enormous prospects to positively impact prevention, diagnosis, treatment, and living with kidney diseases.

•    Empowering Patients to Choose Kidney Healthy Foods
•    Fostering Innovation in Fluid Management 
•    Identification of Appropriate Endpoints for Clinical Trials in Hyperoxaluria 
•    Surrogate Endpoints in Focal Segmental Glomerulosclerosis (FSGS)
•    Towards Minimizing Glucocorticoid Use in ANCA Vasculitis and Lupus Nephritis: Can Systematic Assessment of Glucocorticoid Induced Damage Pave the Way? 

Once the portal closes, the KHI Board of Directors will review the proposals, score them based on their feasibility, impact, and likelihood to meet the KHI Mission. Meritorious proposals will be officially endorsed this summer. Once endorsed by the Board, interested individuals can apply to serve on KHI project workgroups this fall. 

In its fifth year, KHI will continue to achieve growth and interaction among its diverse membership in order to facilitate development, dissemination, and implementation of drugs, devices, and biologics that improve kidney health. If interested in receiving more information about KHI or enrolling as a member, please contact the KHI staff at KHI@asn-online.org.

 

KHI would like to acknowledge and thank all of the members of the 2017 KHI Program Planning Committee for their efforts in planning and organizing the Fifth Annual KHI Stakeholders Meeting.

Matthew Breyer, MD, FASN
Michael Flessner, MD, PhD
Victor Gura, MD, FASN
Carolyn Y. Neuland, PhD
Uptal Patel, MD
Alan Perlman, MD
Katherine Tuttle, MD, Chair
Prabir Roy-Chaudhury, MD, PhD, KHI Co-Chair
David M. White, KHI PFPC Liaison